Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 31.
doi: 10.1038/s41587-025-02610-2. Online ahead of print.

Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo

Affiliations

Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo

Huiying Li et al. Nat Biotechnol. .

Abstract

Tunable and reversible regulation of exogenous and endogenous gene expression would be useful for improving the safety and efficacy of gene therapy. Current chemically inducible systems are limited by the rapid diffusion and extended metabolism of small molecules, and associated side effects. Here we develop a photoactivatable RNA adenosine base editor (PA-rABE) by harnessing a compact Cas13 variant and a split ADAR2 deaminase fused with the Magnets system, which is activated through blue-light-induced dimerization. PA-rABE achieves highly efficient editing on endogenous RNA with minimal bystander editing and off-target effects. By editing a phosphorylation site of the endogenous CTNNB1 gene, PA-rABE stabilizes the β-catenin protein and activates Wnt signaling in vivo. Using adeno-associated virus vectors to deliver PA-rABE along with an hF9 variant containing a premature termination codon, we show amelioration of clotting defects in hemophilia B mice upon illumination. In summary, PA-rABE offers a controlled RNA base-editing technology for diverse biomedical applications, enabling reversible and spatiotemporally specific modulation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: A patent application (application number PCT/CN2024/124011) based on the results reported in this study has been submitted but not yet authorized. The patent applicant is East China Normal University, and D.L., H.L., Y.Q., B.S., X.Q. and M.L. are the inventors. The other authors declare no competing interests.

References

    1. Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020). - PubMed - PMC - DOI
    1. Pacesa, M., Pelea, O. & Jinek, M. Past, present, and future of CRISPR genome editing technologies. Cell 187, 1076–1100 (2024). - PubMed - DOI
    1. Zhong, G. et al. A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo. Nat. Biotechnol. 38, 169–175 (2020). - PubMed - DOI
    1. Monteys, A. M. et al. Regulated control of gene therapies by drug-induced splicing. Nature 596, 291–295 (2021). - PubMed - PMC - DOI
    1. Liu, R. et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat. Biotechnol. 40, 779–786 (2022). - PubMed - DOI

LinkOut - more resources